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The cyclin-dependent kinase (Cdk)-cyclin D/retinoblastoma (pRb)/E2F cascade, which controls the G1/S transition of cell
cycle, has been found to be altered in many neoplasias. Inhibition of this pathway by using, for example, selective Cdk4
inhibitors has been suggested to be a promising approach for cancer therapy. We hypothesized that appropriately radiolabeled
Cdk4 inhibitors are suitable probes for tumor imaging and may be helpful studying cell proliferation processes in vivo
by positron emission tomography. Herein, we report the synthesis and biological, biochemical, and radiopharmacological
characterizations of two 124I-labeled small molecule Cdk4 inhibitors (8-cyclopentyl-6-iodo-5-methyl-2-(4-piperazin-1-yl-
phenylamino)-8H-pyrido[2,3-d]-pyrimidin-7-one (CKIA) and 8-cyclopentyl-6-iodo-5-methyl-2-(5-(piperazin-1-yl)-pyridin-2-
yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one (CKIB)). Our data demonstrate a deﬁned and speciﬁc inhibition of tumor cell
proliferation through CKIA and CKIB by inhibition of the Cdk4/pRb/E2F pathway emphasizing potential therapeutic beneﬁt
of CKIA and CKIB. Furthermore, radiopharmacological properties of [124I]CKIA and [124I]CKIB observed in human tumor cells
are promising prerequisites for in vivo biodistribution and imaging studies.
Copyright © 2009 Franziska Graf et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
T h el a c ko fg r o w t hc o n t r o li nt u m o rc e l l si sar e s u l to f
alterations in a variety of molecules and regulatory pathways
involved in cell cycle control [1]. In particular, the transition
from G1 to S phase is deregulated in cancer [2]. Progression
of G1 phase is promoted by active complexes of cyclin-
dependent kinases (Cdks) and cyclins [2]. Among them
serine-threonine kinase Cdk4 triggers an important cascade
of events in G1 phase. Cdk4 associated with its cofactor
cyclin D catalyzes phosphorylation of retinoblastoma family
proteins (pRb). Nuclear proteins pRb exhibit numerous
threonine or serine residues as phosphorylation sites [3, 4].
pRb interact as pocket proteins by binding and inhibiting
critical regulatory proteins, including transcription factors
of E2F family [2]. Thus, pRb act as suppressors of cellular
proliferation and regulators of cell cycle in mammalian cells
[5]. Phosphorylation of pRb by Cdk4-cyclin D at speciﬁc
site Ser780 inactivates pRb and leads to release of E2F
proteinsfromtheinhibitorypRb-E2F-complex[6].Asacon-
sequence transcription of E2F-regulated genes is promoted.
E2F family proteins regulate expression of genes, whose
protein products are necessary for cell cycle progression,
apoptosis, and DNA repair [7]. Thereby, among other cell
cycle dependent gene expressions of E2F-1 or proliferating
cell nuclear antigen (PCNA), a cofactor of DNA polymerases
that encircles DNA, is activated [8, 9].
The disruption and hyperactivation of the Cdk4-cyclin
D/pRb/E2F pathway in most cancer types such as malignant
sarcomas, gliomas, and breast carcinomas [1, 10–12]h a v e
made the Cdk4-cyclin D complex an attractive molecular
target for cancer therapy [13]. Speciﬁc inhibition of Cdk4-
cyclin D results in pRb hypophosphorylation which prevents
cell proliferation and further tumor growth.2 Journal of Oncology
In recent years, a large number of selective Cdk4
inhibitors have been described in medicinal chemistry liter-
ature [14–16]. In this regard, VanderWel et al. [17, 18]i d e n -
tiﬁed various pyrido-[2,3-d]pyrimidin-7-ones derivatives as
selective inhibitors of the Cdk4-cyclin D complex (IC50 2–
32nM). One of these derivatives (PD 0332991) has entered
clinical trials for cancer therapy [15], for example, an accom-
plished clinical phase I study of oral PD 0332991 in patients
with advanced solid tumors, excluding small cell lung cancer
and retinoblastoma, and an ongoing study of PD 0332991 in
clinical phases I and II in combination with bortezomib and
dexamethasone in patients with multiple myeloma. Among
this series of compounds, an iodine-containing analog
(compound 30 [17]) has also been reported as a potent
Cdk4-cyclin D inhibitor (IC50 5nM) causing inhibition of
tumor cell proliferation. The iodine substituent represents
an attractive site for an isotopic substitution with several
radioiodine isotopes yielding radiolabeled compounds for
molecular imaging purposes.
Within the arsenal of molecular imaging methodolo-
gies, positron emission tomography (PET) represents an
important, noninvasive technique for the development and
evaluation of anticancer strategies through visualization and
assessmentoftissuefunctionandquantiﬁcationofmetabolic
pathways in vivo [19]. PET uses short-lived positron emitters
like carbon-11 (t1/2 = 20.39minutes), ﬂuorine-18 (t1/2 =
109.77minutes) and iodine-124 (t1/2 = 4.18 days) for
labeling of biomolecules. The resulting PET radiotracers
can be used for in vivo imaging to provide quantitative
kinetic information of physiological processes. At present
PET represents the most selective and sensitive method (at
the picomolar to nanomolar level) to depict physiologic,
metabolic, and molecular pathways in vivo. While it lacks the
spatial resolution of other imaging techniques like magnetic
resonance imaging (MRI) or computed tomography (CT), it
is unrivalled in speciﬁcity and kinetic sensitivity. Apart from
its capability to provide pathophysiological information on
human disease, for example, by identiﬁcation of primary
tumors or by tumor staging, PET is also important for the
precise assessment of therapeutic eﬃcacy [19]. PET also has
become an important technique for the development and
evaluation of novel anticancer strategies. Moreover, PET has
also entered the ﬁeld of modern drug development and
evaluation. It provides a unique platform to study pharma-
cokinetics, pharmacodynamics, and the mode of action of
novel drugs in both animal models and humans [20].
Most clinical PET studies use 2-[18F]ﬂuoro-2-deoxyglu-
cose ([18F]FDG) as the radiotracer of choice for tumor
imaging. However, although [18F]FDG-PET allows tumor
imaging with high sensitivity, its application is sometimes
limited by its lack of speciﬁcity as documented by the
inability to discriminate between malignancies and inﬂam-
mation. Therefore, alternative PET radiotracers are required
for speciﬁc tumor imaging and further investigation of
tumorigenic processes [21].
We hypothesize that appropriately 124I-labeled selective
Cdk4 inhibitors represent a novel promising class of PET
radiotracers for imaging and functional characterization of
tumorigenesis in vivo by PET.
Currently, an exact and accurate assessment of Cdk4
protein levels and/or activity in tumors or other tissues can
only be achieved by laborious analyses ex vivo. Moreover,
instability of Cdk4 mRNA and protein leads to further
diﬃculties in terms of the intervals between tissue sampling
and time of analysis. In this line, noninvasive monitoring
by means of nuclear molecular imaging techniques like PET
provides unique opportunities to obtain data on functional
Cdk4 protein expression or activity during tumorigenesis.
Moreover, the development and in vivo study of appropri-
ately radiolabeled selective Cdk4 inhibitors would provide
pharmacological data, which may help to understand their
exact physiological actions and metabolic pathways.
The aim of our study was the biological, biochemical,
and radiopharmacological characterization of two
Cdk4 inhibitors (8-cyclopentyl-6-iodo-5-methyl-2-(4-
piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]-pyrimidin-
7-one (CKIA) and 8-cyclopentyl-6-iodo-5-methyl-2-(5-
(piperazin-1-yl)-pyridin-2-yl-amino)-8H-pyrido[2,3-
d]pyrimidin-7-one (CKIB)) in diﬀerent tumor cell lines.
We investigated cell proliferation, cell cycle distribution,
pRb phosphorylation, and mRNA expression of E2F-1 and
PCNA in tumor cells after treatment with CKIA and CKIB.
Our data demonstrate a deﬁnite and speciﬁc inhibition of
tumor cell proliferation after incubation with CKIA and
CKIB. Moreover, radiotracers [124I]CKIA and [124I]CKIB
were used to study uptake in human tumor cells and
to investigate in vitro stability. The results are important
prerequisites for the design of in vivo biodistribution and
imaging studies to further support our hypothesis that
radiolabeled Cdk4 inhibitors are suitable radiotracers for
tumor imaging by means of PET.
2.MaterialsandMethods
2.1. Radiotracer Synthesis. Compounds [124I]CKIA and
[124I]CKIB were prepared following standard radioiodo-
destannylation protocols as reported by Eisenhut and
Mier [22]. Compounds CKIA and CKIB and the cor-
responding stannylated labeling precursors (CKIAP and
CKIBP) were prepared with small modiﬁcations according
to the procedure described by Barvian et al. [23], and
VanderWel et al. [17]. Radiosynthesis of [124I]CKIA and
[124I]CKIB were performed by 124I-iodination of the corre-
sponding trimethyl stannylated precursors by regioselective
destannylation under mild conditions using [124I]NaI and
chloramine-T or Iodogen as oxidizing agents (Scheme 1).
The preparative synthesis starting from 50μLo fC K I A P
(5mg/mL) and 36.08MBq [124I]NaI using Iodogen pre-
coated tubes as oxidizing agent aﬀorded 11.8MBq (33.6%,
decay-corrected) of [124I]CKIA within 104 minutes, includ-
ing HPLC puriﬁcation.
The optimized reaction conditions for the preparative
[124I]CKIA-synthesis were adopted for the synthesis of
[124I]CKIB. Starting from 50μLo fa5μg/μLC K I B Ps o l u t i o n
in DMSO and 5% glacial acetic acid in methanol (1/3)
and 28.89MBq of [124I ] N a Iw i t h i n1 0 7m i n u t e s7 . 7 8 M B q
(27.8%, decay-corrected) of [124I]CKIB was obtained,Journal of Oncology 3
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Scheme 1: Radiolabeling of CKIAP and CKIBP. a: [124I]NaI, Iodogen, rt, 10 minutes; b: TFA, 50◦C, 30 minutes.
including HPLC puriﬁcation. The speciﬁc activity was
20GBq/μmol for [124I]CKIA and [124I]CKIB, respectively.
2.2. Cell Culture. Human tumor cell lines HT-29, a col-
orectal adenocarcinoma cell line, FaDu, a head and neck
squamous cell carcinoma cell line and THP-1, an acute
monocytic leukemia cell line, were obtained from DSMZ,
Braunschweig, Germany, and cultured in McCoy’s 5A
medium (HT-29) or RPMI 1640 medium (FaDu, THP-1)
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin. THP-1 cells were diﬀerentiated with
64nM 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma-
Aldrich, M¨ unchen, Germany) for 72 hours to macrophage-
like cells (THP-1 macrophage). After that, medium contain-
ing TPA was removed, and cells were replenished with fresh
RPMI medium lacking TPA for respective incubation with
CKIA and CKIB (72hours maximum). During this time
THP-1 macrophage cells remain diﬀerentiated. All cells were
cultured at 37◦C, 5% CO2, and 95% humidity in a CO2
incubator (Heracell, Heraeus, Hanau, Germany).
As a control to classify the eﬀect of CKIA or CKIB,
adherent tumor cells were arrested in G1 phase through
serum-deprivation. First cells were cultured until conﬂuence
and then cell culture medium with only 0.25% FBS was
applied for 72hours.
2.3.CellGrowthStudies. Cellgrowthinhibitionwasanalyzed
for up to 72 hours after treatment of CKIA and CKIB. 2.5 ×
105 cells were seeded into a cell culture ﬂask and incubated
for 24hours. Then 0.1 or 1.0μM of the respective compound
was added into the cell culture media (either every 24hours
oronlyonce)andcellswerecountedwiththeCasyModelTT
cell counter (Schaerfe-System, Reutlingen, Germany) after
24, 48, and 72 hours of incubation with CKIA or CKIB.
2.4. Flow Cytometry. Cell cycle distribution of the cells was
determinedbyﬂowcytometryDNAanalysis.Aftertreatment
of 1 × 106 cells for 24 hours without or with CKIA or
CKIB, cells were washed with PBS and detached from the
cell culture ﬂask by addition of trypsin (HT-29, FaDu) or
accutase (diﬀerentiated THP-1). After centrifugation for 5
minutes at 1000rpm at 4◦C cells were washed twice with
ice-cold PBS and ﬁxed in 70% ethanol at 4◦C for at least
1 hour. Ethanol-ﬁxed cells were washed again, treated with
1μg/mL ribonuclease I (Sigma-Aldrich) for 30 minutes at
37◦C and stained with 10μg/mL propidium iodide (Sigma-
Aldrich) in the dark. Flow cytometry analysis was performed
on an FACSCalibur Flow Cytometer (Becton Dickinson,
Z¨ urich, Switzerland) by use of the CellQuest Pro software.
For cell cycle analysis, 20000 events had been collected in
the single-events region with a total event rate not exceeding
300events/second. Data were analyzed with ModFit LT
software package.
2.5. SDS-PAGE and Western Blot. At the end of treatment
with CKIA or CKIB, cells were washed with ice-cold PBS
and lysed in lysis buﬀer (50mM Tris-HCl pH 7.5, 150mM
NaCl, 0.5% Nonidet P40 with 1mM sodium orthovanadate,
1mMN aF ,10mMβ-glycerophosphate, 1 mM dithiothreitol
(DTT), 1mM phenyl-methyl sulfonyl ﬂuoride, 1mM Pefa-
block, and 1μg/mL Leupeptine). Cells were centrifuged at
15000 ×gf o r1 5m i n u t e sa t4 ◦C. Protein concentration in
thesupernatantswerequantiﬁedusingtheBCAproteinassay
kit (Pierce, Rockford, USA) according to the manufacturer’s
recommendations and bovine serum albumin as protein
standard.
25–50μg of protein were mixed with sample buﬀer,
denatured at 95◦C for 5 minutes and separated on 7.5%
sodium-dodecylsulfate (SDS)-polyacrylamide gels for pRb
detection. After electrophoresis proteins were transferred to
nitrocellulose membranes by electroblotting and blocked for
1h o u ra tr o o mt e m p e r a t u r ei nT B S / T w e e n( 5 0 m MT r i s -
HCl pH 8.0, 150mM NaCl, 0.05% Tween-20) containing
5% nonfat milk. Membranes were incubated with the
primary antibodies Phospho-Rb(Ser780) (1 : 1000, no.
9307 Cell Signaling Technology) or Rb(4H1)mAb (1 :
2000, no. 9309, Cell Signaling Technology) at 4◦Co v e r
night followed by incubation with secondary peroxidase-
conjugated antibodies antirabbit IgG (1 : 10000, A0545,
Sigma-Aldrich) or antimouse IgG (1 : 10000, A9044, Sigma-
Aldrich) for 1 hour at room temperature. After washing
with TBS/Tween proteins were visualized by chemilumines-
cence using the SuperSignal West Pico Chemiluminescent
Substrate (Pierce, Rockford, USA) and exposed to Kodak
BioMax light ﬁlms (Sigma-Aldrich) for 5–15 minutes. In
order to detect a second protein, blots were stripped by
incubation with 62.5mM Tris-HCl pH 6.7, 2% SDS and
0.7% β-mercaptoethanol at 55◦C for 15 minutes. After
that, again incubation with primary polyclonal antibody
anti-β-actin IgG (1 : 1000, A5060, Sigma-Aldrich) and4 Journal of Oncology
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Figure1:CellproliferationrateofHT-29,FaDu,THP-1,andTHP-1macrophageaftertreatmentwith(a)CKIAor(b)CKIB(every24hours)
in percentage of control without treatment. (c) Comparison of daily treatment and single treatment after 72 hours of incubation with 1μM
CKIA or CKIB, respectively. (means ± standard deviations, n ≥ 6, ANOVA, ∗P<. 05, compared to control (100%)).
secondary peroxidase-conjugated antibody antirabbit IgG
(1 : 10,000, A0545, Sigma-Aldrich), and protein detection
was performed as described above.
2.6. RNA Preparation and One-Step Quantitative Real-Time
RT-PCR. After 24-hour-incubation with CKIA or CKIB
RNA was extracted using the miRNeasy Mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. RNA was treated with RNase free DNase (Fermentas,
St. Leon-Roth, Germany) according to the manufacturer’s
guidelines to prevent genomic DNA contamination. The
reverse transcription and quantitative real-time PCR of
speciﬁc mRNA was carried out in one step from 50ng of
total RNA and intron-spanning primers (Metabion, Munich,
Germany) using the QuantiTect SYBR Green RT-PCR kitJournal of Oncology 5
Table 1: Primer sequences and annealing temperatures for quantitative real-time RT-PCR.
Primer bp pos. Tannealing/◦C Sequence
β-actin-f 736 – 755 59 5 -GGA CTT CGA GCA AGA GAT GG-3 
β-actin-r 969 – 950 5 -AGC ACT GTG TTG GCG TAC AG-3 
E2F-1-f 796 – 815 58 5 -AGC TGG ACC ACC TGA TGA AT-3 
E2F-1-r 945 – 926 5 -GAG GGG CTT TGA TCA CCA TA-3 
PCNA-f 444 – 463 56 5 -GGC GTG AAC CTC ACC AGT AT-3 
PCNA-r 688 – 669 5 -TCT CGG CAT ATA CGT GCA AA-3 
(Qiagen) according to the manufacturer’s instructions. The
primer sequences and annealing temperatures are given
in Table 1. One-step quantitative real-time RT-PCR was
performed in a mastercycler ep Realplex system (Eppendorf,
Hamburg, Germany). RNA samples were reverse tran-
scripted for 20 minutes at 50◦C. Then, quantitative real-time
PCR was performed for 40 cycles with denaturation at 95◦C
for 20 seconds, annealing at 56 to 59◦C (depending on the
primers, Table 1) for 20 seconds and extending at 68◦Cf o r
30 seconds. All PCR products were checked by melting point
analysis upon completion of PCR cycles by heating up from
55 to 95◦Ci n2 0m i n u t e s .
For each cell line and treatment two to four diﬀerent
RNA samples were analyzed as triplicates. A negative control
without RNA template was included in every measurement
for the diﬀerent primers. For each experimental sample,
mRNA levels were normalized to β-actin mRNA levels
(threshold cycle β-actin—threshold cycle mRNA of interest
= ΔCt). Therefore primers for the ampliﬁcation of β-actin
were included in every measurement to correct for sample-
to-sample variations. mRNA levels were presented as 2ΔΔCt
(ΔΔCt = ΔCt (treatment)− (ΔCt(control)).
2.7. Stability and Radiotracer Uptake Studies. Stability of
[124I]CKIA and [124I]CKIB was examined after 1 hour at
37◦Ci nd i ﬀerent physiological buﬀers (pH 4.2, 7.4, 9.0), cell
culture medium, and rodent plasma by HPLC analysis.
For radiotracer uptake experiments, 5 × 104 cells were
seeded in a cavity of a 24-well plate (Greiner, Frickenhausen,
Germany) and cultured in a humidiﬁed atmosphere of 5%
CO2 at 37◦C using the above-mentioned cell culture media.
After overnight incubation, 0.5mL of cell culture medium
with about 30kBq [124I]CKIA or [124I]CKIB was added and
incubation was continued for several time points at 37◦C
and 4◦C. Subsequently, cells were washed three times with
ice-cold PBS and lysed in 0.5mL 0.1M sodium hydroxide
with 1% SDS. Cell lysates were counted with a Cobra II
gamma counter (Canberra-Packard, Meriden, CT, USA).
Protein levels were quantiﬁed using the BCA protein assay
kit (Pierce, Rockford, USA) according to the manufacturer’s
recommendations and bovine serum albumin as protein
standard. Uptake data for all experiments are expressed as
percent of injected dose per mg protein (%ID/mg protein).
2.8. Statistical Analysis. Descriptive data were expressed as
arithmetic means ± standard deviations. The number of n
in the ﬁgure legends represents the number of independent
experiments. Statistical analyses were performed using one-
way ANOVA or Wilcoxon signed rank test. ANOVA was
coupled with a post hoc Bonferroni correction analysis
when appropriate. Spearman’s rank correlation coeﬃcient
was calculated between data related to Cdk4 activity and
radiotracer uptake. For all analyses a value of P<. 05 was
considered as statistically signiﬁcant. The SPSS statistical
software package (version 12.0 for Windows; SPSS Inc.,
Chicago, IL, USA) was used for all analyses.
3. Results
3.1. Cell Growth Studies. For the characterization of cell
cycle inhibitors CKIA and CKIB three diﬀerent tumor
cell lines were studied with respect to their concentration
dependent cell proliferation. Cell growth studies showed
very diﬀerent growth curves for all tumor cell lines. HT-29
cells show with 17 hours the shortest doubling time. For
FaDu cells a doubling time of 22 hours and for THP-1 cells
of 38 hours could be observed in logarithmic phase. For
all experiments with CKIA and CKIB tumor cells were in
logarithmic growth phase. After 72 hours of incubation with
TPA, THP-1 monocyte-like suspension cells adhere almost
completely at the bottom of culture ﬂask and diﬀerentiate to
macrophage-like cells. TPA diﬀerentiated THP-1 cells (THP-
1 macrophage) showed no more cell proliferation and served
a sc o n t r o lc e l lm o d e l .
T u m o rc e l lg r o w t hs t u d i e sw i t hC K I A( e v e r y2 4h o u r s
treatment)indicated a signiﬁcantly reduced cellproliferation
in all tumor cell lines at 48 and 72 hours after treatment
with 0.1 (<50%) and 1μM( <25%) of CKIA (Figure 1, P<
.05). Nonrecurring treatment with 1μMo fC K I Af o r7 2
hoursprovidedsimilarﬁndingscomparedtotreatmentevery
24 hours. Also in THP-1 macrophages, cell number was
decreased by 33% with 0.1μMo fC K I A( Figure 1).
Generally, CKIB showed similar eﬀects on cell prolif-
eration, albeit these eﬀects were only achieved at higher
CKIBconcentrationsorbylongerincubationtimecompared
to CKIA. After 48 hours of treatment with CKIB, cell
proliferation in HT-29 cells was reduced by 35% (0.1μM)
and 61% (1.0μM), respectively, in FaDu cells 29% (0.1μM)
and 46% (1.0μM), respectively, and in THP-1 cells 20%
(0.1μM) and 46% (1.0μM), respectively (Figure 1, P<
.05). 72 hours after treatment with 1.0μMo fC K I Bc e l l
proliferation was decreased to 35, 45, or 28% (HT-29, FaDu,
THP-1). Cell number of THP-1 macrophage cells for this
incubation condition was also signiﬁcantly depleted.6 Journal of Oncology
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Figure 2: Cell cycle distribution of HT-29 cells at 24 hours after treatment with CKIA or CKIB (representative histograms).
3.2. Cell Cycle Analysis. CKIA and CKIB were analyzed for
their eﬀects on cell cycle distribution. Already 24 hours after
incubation with CKIA the percentage of tumor cells in G1
phase showed a concentration dependent increment of up to
89.9% in HT-29 and 84.5% in FaDu tumor cells (Figure 2,
Table 2, P<. 05).
CKIA induced a G1 phase arrest after incubation with
0.05, 0.1, and 0.5μM in THP-1 cells. At higher concentration
of 1.0μM, however, cell cycle distribution switched back
to values obtained for untreated cells. Over 89% of HT-29
and THP-1 cells in G1 phase were obtained after 24 hours
of incubation with 1.0μMo fC K I B( Table 2, P<. 05). A
concentration dependent alteration of cell cycle distribution
after incubation with CKIB was also observed in FaDu cells,
but 24 hours after incubation with 1.0μMo fC K I Bo n l y
70.7% were achieved in G1 phase. THP-1 macrophage cells
showed no change in percentage of G1 phase neither after
incubation with CKIA nor with CKIB.
3.3. pRb Phosphorylation. To study the interaction of CKIA
or CKIB with Cdk4 and the inﬂuence on the downstream
signaling pathway, detection of pRb phosphorylation status
in whole cell lysates was performed by Western Blot.
Cdk4 speciﬁc phosphorylation of pRb on Ser780 and were
normalizedtototalamountofpRb,β-actinservedasinternal
control. In all cell lines antibodies Phospho-Rb(Ser780)
and Rb(4H1)mAb only recognized endogenous pRb species
with a size of 110kDa. The total levels of pRb remained
constant in all cell lines, only incubation with 1μMC K I A
by trend showed a decrease of total pRb. After incubation
with CKIA a concentration dependent hypophosphorylation
of pRb(Ser780) was found (Figure 3). pRb(Ser780) phos-
phorylation was decreased three- to tenfold after 24 hours
of treatment with 0.1 and 1μM CKIA in all cell lines.
Results of pRb(Ser780) phosphorylation analyses suggested
a downregulation after 24 hours of incubation with 1μM
of CKIB in HT-29 cells (Figure 3). No signiﬁcant change
in pRb(Ser780) phosphorylation status of FaDu and THP-1
cells incubated with CKIB was found.
3.4. E2F-1 and PCNA mRNA Expression. mRNA expression
of pRb eﬀected E2F-1 and PCNA genes was measured
in relation to the eﬀects of CKIA and CKIB on Cdk4
downstream signaling pathway. For grading and comparison
of the studied eﬀects also mRNA levels of serum-deprived
G1 arrested adherent cells were detected. A substantial
downregulation of E2F-1 and PCNA mRNA expression
could be demonstrated after incubation with 1μMo fC K I A
in all cell lines studied (Figure 4).
I nH T - 2 9a n dT H P - 1t u m o rc e ll sa nu pt o1 5 %r e d u ct i o n
of mRNA expression for both genes (E2F-1 and PCNA)
compared to control without treatment was detectable. In
HT-29andFaDucellsmRNAexpressionofE2F-1andPCNA
was in the range of corresponding levels in G1 arrested
cells.Furtheranalysisofreleasedserum-deprivedHT-29cells
after 24 hours incubation with CKIA exhibited a consistent
downregulation of both E2F-1 and PCNA mRNA (data not
shown). Also E2F-1 and PCNA mRNA expression analysesJournal of Oncology 7
Table 2: Percentage of cells in G1 phase after 24 hours of treatment with diﬀerent concentrations of CKIA or CKIB (values are means ±
standard deviations in %, n ≥ 8, ∗P<. 05, compared to control (0μM), resp.).
CKIA/μM 0 0.05 0.1 0.5 1.0
HT-29 45.6 ± 4.1 62.3 ± 4.0∗ 68.1 ± 4.1∗ 90.1 ± 1.4∗ 89.9 ± 0.8∗
FaDu 46.4 ± 4.7 55.7 ± 6.5∗ 56.9 ± 6.5∗ 82.2 ± 2.5∗ 84.5 ± 3.1∗
THP-1 58.8 ± 4.5 87.3 ± 8.0∗ 92.1 ± 3.2∗ 86.2 ± 5.2∗ 61.7 ± 6.4
THP-1 macrophage 46.9 ± 5.9 45.1 ± 1.8∗ 51.9 ± 3.3 45.3 ± 1.5∗ 41.4 ± 2.0∗
CKIB/μM 0 0.05 0.1 0.5 1.0
HT-29 46.7 ± 2.4 54.0 ± 1.5∗ 58.7 ± 2.7∗ 81.5 ± 4.9∗ 89.9 ± 4.3∗
FaDu 58.6 ± 3.4 64.7 ± 3.5∗ 65.8 ± 5.4∗ 69.4 ± 6.1∗ 70.7 ± 3.6∗
THP-1 59.9 ± 1.8 68.6 ± 2.8∗ 73.5 ± 1.0∗ 86.8 ± 1.7∗ 89.1 ± 1.0∗
THP-1 macrophage 52.2 ± 3.2 53.2 ± 2.4 53.6 ± 2.0 55.4 ± 2.0 54.6 ± 2.7
HT-29 FaDu
pRb(Ser780)
pRb
0 0.1 1
CKIA CKIB
0.1 1 0 0.1 1
CKIA CKIB
0.1 1
β-actin
μM μM
(a)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0
0.2
0.4
0.6
0.8
1
1.2
1.4
p
R
b
(
S
e
r
7
8
0
)
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
r
e
l
a
t
i
v
e
t
o
t
o
t
a
l
p
R
b
HT-29 FaDu THP-1 THP-1
macrophage
HT-29 FaDu THP-1 THP-1
macrophage
CKIA
CKIB
Without treatment
0.1μM
1μM
(b)
Figure 3: (a) Representative Western blots of HT-29 and FaDu cell
lysates. (b) pRb phosphorylation at Ser780 relative to total pRb
(means ± standard deviations, n = 2–5).
after 24 hours of incubation with 1μM of CKIB indicated
a downregulation in all cell lines and THP-1 macrophages.
Expression of E2F-1 and PCNA mRNA was decreased by
CKIB up to 60% in FaDu or HT-29 cells, but without
statistical signiﬁcance.
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Figure 4: mRNA expression level of E2F-1 and PCNA after 24-
hour-incubation with (a) CKIA or (b) CKIB and in G1 arrested
adherent tumor cells after serum-deprivation relative to control
cells without treatment (means ± standard deviations, n ≥ 6).8 Journal of Oncology
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Figure 5: Cellular radiotracer uptake of (a) [124I]CKIA and (b)
[124I]CKIB over a period of 5 hours at 37◦C and 4◦C (means ±
standard deviations, n = 4, ANOVA, P<. 05, 4◦C compared
to 37◦C, resp.). Symbols represent observed data, lines represent
computer-derived ﬁts.
3.5. Stability and Radiotracer Uptake Studies. Preliminary
experiments with [124I]CKIA and [124I]CKIB indicated a
suﬃcient stability of this compounds in various buﬀers (pH
4.2, 7.4, and 9.0), cell culture media, and rodent plasma
samples in the range of 93–97% at 37◦Cf o r1h o u ra t
minimum.
In vitro radiotracer uptake studies in adherent tumor
cells using [124I]CKIA and [124I]CKIB showed substantial
uptake in HT-29 and FaDu cells (Figure 5).
The time-dependent cellular uptake was similar in both
cell lines and uptake of [124I]CKIA is steadily increased with
timeupto5hours.After2hoursat37◦C1649±117%ID/mg
protein in HT-29 and 1033 ± 84%ID/mg protein in FaDu
cells were obtained. At 4◦C an obvious lower uptake was
detectablein both celllines (258±30 %ID/mg protein in HT-
29, 169 ± 14%ID/mg protein in FaDu, P<. 05). In vitro
studies with [124I]CKIB demonstrated a radiotracer uptake
of 904 ±43%ID/mg protein in HT-29 and 856±45 %ID/mg
protein in FaDu cells after 2 hours at 37◦C. Radiotracer
uptake of [124I]CKIB was only marginally increased up to
5 hours at 37◦C and again radiotracer uptake at 4◦Cw a s
substantially lower compared to 37◦C( P<. 05).
4. Discussion
In 2005, CKIA was reported as a speciﬁc and potent Cdk4
inhibitorwithanIC50 valueof5nMbyVanderWeletal.[17],
but in spite of promising properties only marginal examina-
tions concerning inhibition of tumor cell proliferation were
performed.
The purpose of our study was the further evaluation of
the known Cdk4 inhibitor CKIA and of a new derivative
compound CKIB concerning their biological, biochemical,
and radiopharmacological properties, to proof the feasibility
and suitability of these Cdk4 inhibitors for radiotracer
development and imaging of cell proliferation processes in
vivo especially in tumor entities. CKIB was designed as a
less lipophilic analog of Cdk4 inhibitor CKIA to reduce
nonspeciﬁc binding.
To the best of our knowledge, for the ﬁrst time Cdk4
inhibitors CKIA and CKIB were demonstrated to act as
tumor cell growth inhibitors via speciﬁc inhibition of
Cdk4/pRb/E2F signaling pathway and induction of G1 arrest
in cells.
For our studies, HT-29, FaDu, and THP-1 cells were used
as continuously proliferating cell models. The three tumor
cell lines represent common models for human solid tumors
(HT-29, FaDu) and leukemia (THP-1). Furthermore, TPA
diﬀerentiated THP-1 cells served as a cellular model that
shows no cell proliferation potential due to their arrest in
cell cycle. The tumor cell lines studied exhibited diﬀerent
doubling rates, which could inﬂuence the impact of cell cycle
inhibitors. However, cell proliferation after treatment with
CKIA or CKIB showed no conspicuous diﬀerences between
rapid proliferating HT-29 or slower proliferating FaDu
and THP-1 cells, respectively. In all cell lines a signiﬁcant
concentration and time dependence of cell division was
observedafterapplicationwithCKIAorCKIB.Indeed,CKIB
is not as potent as CKIA to inhibit cell growth. After 72
hours of incubation with 1.0 μMo fC K I Ao rC K I Bad ec r e a s e
in cell number about 55–90% compared to control without
treatment could be found in tumor cells. CKIA and CKIB
inhibit cell division, but no decrease of cell number under
the seeded cell number was observed after incubation with
CKIA or CKIB. Control cells THP-1 macrophage only show
decreased cell numbers after 72 hours of incubation with
CKIB. Hence, no acute cytotoxic eﬀect of CKIA or CKIBJournal of Oncology 9
is assumed. Interestingly, also nonrecurring treatment with
1.0μM of compounds for 72 hours showed similar cell
number values as for ever 24 hours treatment, which could
beanindicationforgoodavailabilityand/orstabilityofactive
CKIA and CKIB in the cells. It is likely, because of action of
CKIA and CKIB in the nucleus, that these compounds are
not accessible for transport outside of cells, for example, by
multidrug resistance proteins (MDR).
Measurement of cell cycle distribution clariﬁed and
complemented the observed data of cell growth studies. 24
hours after incubation with CKIA or CKIB a concentration
dependent increment of cells in G1 phase was detectable
in all tumor cell lines. Cell cycle distribution of THP-
1 macrophage cells remained constantly. Unlike to cell
growth studies, diﬀerences between the tumor cell lines after
treatment with a certain concentration of CKIA or CKIB
were found. Cell cycle distribution studies demonstrated a
lower increment of percentage of FaDu cells in G1 phase
compared to HT-29 or THP-1 cells. For example, 24 hours
after incubation with 0.1μM CKIA percentage of cells in
G1 phase raised up 10.5% in FaDu, 22.5% in HT-29, and
33.4% in THP-1 cells. Surprisingly, at a concentration of
1.0μM of CKIA cell cycle distribution values in THP-1
cells were observed similar to untreated cells. A comparable
phenomenon was obtained by Toogood et al. [18], in human
breast carcinoma cells MDA-MB453 after treatment with
other pyrido[2,3-d]pyrimidin-7-one derivatives identiﬁed as
Cdk4 inhibitors. This unexpected characteristic of cell cycle
distribution observed for a few Cdk4 inhibitors at higher
concentrations(>1.0μM)isstillnotunderstoodandrequires
further investigations to clarify this phenomenon.
The eﬀect of CKIA on cell cycle distribution was consid-
erably higher compared to CKIB at the same concentration
range. Nevertheless, both CKIA and CKIB caused a cell cycle
arrest in G1 phase (G1 ≥ 85%) in tumor cell lines HT-29,
FaDu, and THP-1, although a higher concentration of CKIB
is required to obtain the same extent of cell cycle arrest. Only
in FaDu cells CKIB failed to reach an increment of G1 phase
exceeding 85% (achieved for 1μM CKIA) under conditions
determined. After incubation with 1.0 μM CKIB only 70.7%
of FaDu cells were achieved in G1 phase.
To further characterize the cell cycle arrest, we ana-
lyzed the Cdk4 speciﬁc pRb phosphorylation status and
mRNA levels downstream of Cdk4-cyclin D/pRb pathway.
Rb gene is mutated in some types of cancer [24, 25]
and nonfunctional pRb evades regulation through Cdk-
induced phosphorylation [26]. As inhibitors for the Cdk4-
cyclin D/pRb pathway, compounds CKIA and CKIB should
inhibit cell proliferation and pRb phosphorylation of cells
with functional pRb. HT-29 and FaDu are tumor cell lines
with normal pRb status [27, 28], and also in THP-1 cells
full length pRb is found, which indicate the existence of
functional pRb in these tumor cell line [29]. More than ten
phosphorylation sites of pRb are known in vivo [3]. During
G1/S transition Cdk4/6-cyclin D and Cdk2-cyclinA/E are
involved in pRb phosphorylation, but diﬀerent speciﬁcity of
serineresiduesofpRbwereidentiﬁedforthesediﬀerentCdk-
cyclin-complexes [4, 30]. While Cdk4-cyclin D eﬃciently
and speciﬁcally phosphorylates pRb on Ser780 and Ser795,
Cdk2-cyclin A/E does not. Analyses of pRb phosphorylation
resulted in a signiﬁcantly decreased Ser780 phosphorylation
in all cell lines studied dependent on concentration of CKIA.
After 24 hours of incubation with CKIB a tendency of
pRb hypophosphorylation on Ser780 in HT-29 and THP-
1 macrophage cells was observed. Additional experiments
with speciﬁc antibodies against phospho-Ser795 of pRb also
demonstrated a CKIA concentration dependent decrease of
pRb phosphorylation. The cell cycle regulatory activity of
pRb is especially mediated through its binding of transcrip-
tional factors like E2F, which regulates growth-promoting
genes[5].pRbphosphorylatedonSer780cannotbindtoE2F
transcription factors in vivo [30] and as a consequence of
pRb release from the pRb-E2F complex mRNA expression
of E2F regulated genes, for example, E2F-1 or PCNA is
activated [8, 31]. A substantial downregulation of both E2F-
1 and PCNA mRNA expression was found after 24 hours
of incubation with CKIA in all cell lines. The mRNA levels
in HT-29 and FaDu with 1.0μM of CKIA are comparable
to that of serum-deprived cells arrested in G1 phase. Also
after treatment with 1.0μMo fC K I Bad e c r e a s e dm R N A
expression of E2F-1 and PCNA was detectable. In summary,
our data report a distinct inhibition of pRb phosphorylation
by Cdk4-cyclin D as the consequence of CKIA and CKIB
eﬀects in cells. Reduced pRb phosphorylation leads to a
disruption of the E2F cascade, exempliﬁed for E2F-1 and
PCNA mRNA expression. It can be assumed that other
genes downstream of Cdk4-Cyclin D/pRb/E2F pathway are
aﬀected through CKIA and CKIB induced inhibition of
pRb phosphorylation, for example, genes essential for DNA
duplicationandcellcyclecontrollikeDNApolymeraseαand
cyclinE.TheinﬂuenceofCKIAandCKIBtotheCdk4-cyclin
D/pRb/E2Fpathwayﬁnallyendsincellcyclearrestandastop
of cell proliferation.
CKIA, a pyrido[2,3-d]pyrimidin-7-one derivative, was
reported by VanderWel et al. [17], in 2005 for the ﬁrst
time as a speciﬁc and potent Cdk4 inhibitor with an IC50
value of 5nM. All derivative compounds synthesized by
this group were classiﬁed concerning their inhibition of
diﬀerent kinases by means of IC50 values measured by in
vitro kinase assays. IC50 values allow a comparison between
diﬀerent compounds, but no inferential evidence about their
properties in cells can be made. Furthermore, cell eﬀective
concentration is much higher than IC50 value determined
by an in vitro kinase assay, due to the two barriers cell
membrane and nuclear membrane that have to be overcome,
and possible metabolism of the compound within the cell.
Eﬀective concentration also depends on tumor cell type
and tissue origin. Hence, IC50 values determined by in
vitro kinase assays should not be the only discriminating
argument for choice of a suitable compound for therapeutic
applications.
In our opinion, ﬂow cytometry is a meaningful, fast,
and reproducible method for evaluation of selective cell cycle
inhibitorsconcerningtheireﬀectincells.Previousevaluation
of CKIA in consideration of tumor cell growth inhibition of
human colon carcinoma cell line HCT116, measuring the
[14C]-thymidine incorporation, resulted in an IC50 value of
0.104μM[ 17]. Although a direct comparison is not possible10 Journal of Oncology
becauseofvariationsinmethodsandconditions,thisﬁnding
correlates very well with our data observed for human colon
carcinoma cell line HT-29 by ﬂow cytometry. In HT-29,
an ED50 value of 0.095μM CKIA could be calculated for
increased percentage of cells in G1 phase. In conclusion,
among others ﬂow cytometry would be a good alternative
for inhibitor classiﬁcation.
However, VanderWel et al. has focused on other deriva-
tives of pyrido[2,3-d]pyrimidin-7-one, regarding to the
reduced selectivity of CKIA compared to other compounds
investigated [17]. PD 0332991 has been extensively char-
acterized among other highly selective inhibitors concern-
ing biochemical and biological properties in vitro and in
vivo [15, 32]. In consequence PD 0332001 was scheduled
for clinical trials in 2004 in combination with common
chemotherapeutics. The question to be answered is, if
exceeding high selectivity of pyrido[2,3-d]pyrimidin-7-one
derivativesagainstotherCdksthanCdk4willbeofoutstand-
ing importance for tumor treatment. An expanded eﬀect on
diﬀerent Cdks could also be imaginable for eﬀective tumor
cell growth inhibition.
In summary, CKIA and also the new compound CKIB
were demonstrated to act as tumor cell growth inhibitors
via speciﬁc inhibition of Cdk4-Cyclin D/pRb/E2F signaling
pathway. The mechanism of action conﬁrms the therapeutic
beneﬁt of these compounds in ﬁeld of cancer treatment,
although their lowered selectivity.
We hypothesized that potent Cdk4 inhibitors, which
are suitable for cancer therapy, are also of interest as
radiotracersforimagingofcellproliferationprocessesinvivo
and especially for tumor visualization by positron emission
tomography (PET).
For PET imaging application, beside the knowledge
about biological and biochemical eﬀectiveness of potent
Cdk4 inhibitors also radiopharmacological characterization
of respective radiotracers is required.
Based on the structure of the two compounds CKIA and
CKIB appropriate radiolabeling strategies were designed and
radiolabeling with the positron-emitting nuclide iodine-124
wasperformed(decay-correctedradiochemicalyields:33.6%
[124I]CKIA, and 27.8% [124I]CKIB, purity: >98%, resp.).
Using [124I]CKIA and [124I]CKIB stability and radiotracer
uptake studies were performed in HT-29 and FaDu cells.
In both tumor cell lines a substantial cellular uptake of
[124I]CKIA and [124I]CKIB was observed at 37◦C. The
early uptake kinetics of both compounds was comparable
in both tumor cell lines. In posterior phase (>1hour)
[124I]CKIA showed a higher cellular uptake compared to
[124I]CKIB. Of note, [124I]CKIB uptake level remained
nearly constant after 1hour. This is consistent with the
diﬀerent therapeutic potency of CKIA and CKIB observed
in tumor cell inhibition studies. At lower temperature
of 4◦C obvious lower uptakes were detected for both
compounds. This ﬁnding indicates an energy dependent
mechanism for uptake into cells. In the literature no
analysis or information concerning transport mechanism
ofpyrido[2,3-d]pyrimidin-7-one derivativeswerepublished.
Pyrido[2,3-d]pyrimidin-7-one derivatives were predicted to
bind ATP site of Cdks [23], thus implying a structural
similarity to ATP. Nucleoside transporters (NTs) mediate
the uptake of physiologic nucleosides like adenosine and
were also reported to transport anticancer nucleoside drugs
[33]. Especially, energy-dependent concentrative nucleoside
transporters (CNTs) could be presumed for CKIA and
CKIB transport into cells. Since no speciﬁc pharmacological
inhibitor has been found for CNTs yet [34], it is diﬃcult
to conﬁrm this presumption. Another transporter identiﬁed
to transport nucleotide analogs is MDR5 [35]. Neverthe-
less, the putative transporters still have to be identiﬁed.
The identiﬁcation of speciﬁc transporters of pyrido[2,3-
d]pyrimidin-7-one derivatives will contribute to under-
standing of eﬀectiveness of these compounds and especially
for radiotracer uptake a valuation of tumor accumulation
couldbemadedependingontransporterfrequencyoftumor
species.
Correlation analysis only showed a weak correlation
between E2F-1 mRNA expression as measure of Cdk4
enzyme activity and CKI (CKIA and CKIB) uptake (τ =
0.390, P = .042, n = 15). According to this, the transport of
bothradiotracersintothecellswouldbetheratedetermining
step for cellular uptake of CKIA and CKIB at least in
monolayer cell cultures.
The criteria for therapeutic and imaging agents are very
diﬀerent. A therapeutic active compound must reach and
aﬀect a certain target, whereas the agent for imaging only has
to be retained by the target [36]. Certainly, many other prop-
erties of a radiotracer like biodistribution or lipophilicity
contribute to a speciﬁc tumor accumulation and are relevant
for high-contrast images. The inhibitory eﬀect of CKIA
or CKIB would only be of subordinate interest regarding
the imaging application of these compounds. Nevertheless,
high speciﬁcity and selectivity are a prerequisite for speciﬁc
accumulation in tumor cells. However, a less selective or
speciﬁccompoundwithbetterbiodistributionpropertiesbut
comparable tumor uptake could have advantages for the
application as radiotracer for imaging of tumors by PET.
In summary, our data demonstrate a deﬁnite and speciﬁc
inhibition of tumor cell proliferation when incubated with
CKIA and CKIB due to an arrest of tumor cells in G1 phase.
The repression of G1 progression is achieved by inhibition
of the Cdk4-cyclin D/pRb/E2F pathway. The tumor cell
growth inhibition observed in vitro point out the potential
therapeutic beneﬁt of these compounds, which has to be
proven in further experiments in vivo.
The radiotracer uptake observed in human tumor cells
and the stability of [124I]CKIA and [124I]CKIB as found in
physiological buﬀers are promising prerequisites for in vivo
biodistribution and imaging studies by PET. An interesting
eﬀect arising from the radiotracer uptake studies using
[124I]CKIA and [124I]CKIB is the observed energy dependent
transport of CKIA and CKIB, due to the diﬀerence of
uptake at 37◦Ca n d4 ◦C .T h ep u t a t i v et r a n s p o r t e r ss t i l l
have to be identiﬁed. In this regard, and to further sup-
port our hypothesis that radiolabeled Cdk4 inhibitors are
suitable radiotracers for tumor imaging, comprehensive in
vivo experiments of [124I]CKIA and [124I]CKIB involving
biodistribution and small animal PET studies [37] should be
performed.Journal of Oncology 11
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